Placebo control in Covid-19 trials: A missed opportunity for international guidance.
Indian J Med Ethics
; VI(2): 1-7, 2021.
Article
in English
| MEDLINE | ID: covidwho-1206592
ABSTRACT
Vaccines preventing Covid-19 have been approved in several countries. Is it still ethically acceptable to use placebo controls during the development of other vaccine options? If two of the most influential international guidelines of biomedical research are consulted, the Declaration of Helsinki and the CIOMS-guidelines, the answer is "no". We discuss the implications for ongoing vaccine research, and how placebo controls might be justified nevertheless. However, the ethical conflict remains highly problematic. We suggest that such ethical dilemmas should be avoided in the future by the introduction of a new system of global governance. Once vaccines are approved, a global regulation should oblige producers to provide the necessary amount of vaccine doses for the control groups of ongoing vaccine research.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Placebos
/
Clinical Trials as Topic
/
Guidelines as Topic
/
Ethics, Medical
/
COVID-19 Vaccines
/
COVID-19
/
International Cooperation
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Indian J Med Ethics
Journal subject:
Ethics
Year:
2021
Document Type:
Article
Affiliation country:
IJME.2021.022
Similar
MEDLINE
...
LILACS
LIS